Talzenna: Side Effects & Dosing

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Talazoparib

Indications/Uses

Adult patients w/ germline breast cancer susceptibility gene (BRCA)-mutated (gBRCAm) human epidermal growth factor receptor 2 (HER2) -ve locally advanced or metastatic breast cancer who have previously been treated w/ chemotherapy. In combination w/ enzalutamide for adult patients w/ metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated.

Dosage/Direction for Use

gBRCAm HER2 -ve locally advanced or metastatic breast cancer 1 mg once daily. Renal impairment: Moderate (CrCl 30 to <60 mL/min) 0.75 mg once daily, severe (CrCl 15 to <30 mL/min) 0.5 mg once daily. mCRPC 0.5 mg once daily in combination w/ enzalutamide 160 mg once daily. Renal impairment: Moderate (CrCl 30 to <60 mL/min) 0.35 mg once daily in combination w/ enzalutamide once daily, severe (CrCl 15 to <30 mL/min) 0.25 mg once daily.

Administration

May be taken with or without food.

MIMS Class

Targeted Cancer Therapy

ATC Classification

L01XK04 - talazoparib ; Belongs to the class of poly (ADP-ribose) polymerase (PARP) inhibitors. Used in the treatment of cancer.

Regulatory Classification

POM

Presentation/Packing

Form

Talzenna hard cap 0.1 mg

Packing/Price

1's

Form

Talzenna hard cap 0.25 mg

Packing/Price

1's

Form

Talzenna hard cap 0.35 mg

Packing/Price

1's

Form

Talzenna hard cap 0.5 mg

Packing/Price

1's

Form

Talzenna hard cap 1 mg

Packing/Price

1's

Talzenna

talazoparib

Manufacturer:

Excella